

DR. MATTHIAS WIEDENFELS
Chairman of the Supervisory Board

In the Supervisory Board since: April 2021
Elected until: 2027

Career and Education

- Attorney at law and serial entrepreneur
- Chief Executive Officer, Perspix Biotech GmbH
- Member of the Management Board, BioMedion AG
- Chief Executive Officer, STADA Arzneimittel AG
- Attorney at Law, Ashurst LLP
- Doctorate in Law at Albert – Ludwigs University Freiburg im Breisgau
- Licencié en Droit, University of Montpellier (France)
- Study of Law at Ruprecht-Karls-University, Heidelberg and Albert – Ludwigs University Freiburg im Breisgau,
Law degree

Expertise

Dr. Wiedenfels is Chairman of the Supervisory Board of APONTIS PHARMA AG. He has extensive experience in corporate management, corporate strategy, corporate finance and all aspects of pharmaceutical and corporate law. Dr. Wiedenfels is excellently qualified through his professional expertise in the healthcare market in general and in specialty pharma in particular. His skillset also comprises extensive knowhow and experience in compliance in publicly listed companies. He is well placed to accompany APONTIS PHARMA in the future development of the Company. The Supervisory Board's work will benefit from his industry expertise, transaction experience and management know-how, particularly in view of the planned growth of APONTIS PHARMA.

Memberships in Statutory Domestic Supervisory Boards and in Comparable Domestic and Foreign Supervisory Bodies of Business Enterprises:

- Member of the Supervisory Board at BioMedion Holding GmbH
- Managing Director at Digithep GmbH